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ABSTRACT
PATIENT MOTIVATIONAL LANGUAGE AS A PREDICTOR OF SYMPTOM
CHANGE, HAZARD OF CLINICALLY SIGNIFICANT RESPONSE, AND TIME TO
RESPONSE IN PSYCHOTHERAPY FOR GENERALIZED ANXIETY DISORDER
FEBRUARY 2019
BRIEN J. GOODWIN, B.A., UNIVERSITY OF MASSACHUSETTS AMHERST
M.S., UNIVERSITY OF MASSACHUSETTS AMHERST
Directed by: Professor Michael J. Constantino
Change-talk (CT), or self-arguments for change, has been associated with favorable
patient outcomes, while counter change-talk (CCT), or self-arguments against change,
has been associated with poorer outcomes. Most studies on change language have
focused on the prediction of distal posttreatment outcomes, while the prediction of more
proximal outcomes has remained largely untested. Addressing this gap, we examined
early treatment CT and CCT as predictors of worry change trajectories, “hazard” of
clinically significant response, and time to response (i.e., outcome efficiency) in CBT and
CBT integrated with MI (MI-CBT) for generalized anxiety disorder (GAD). We also
explored whether treatment type moderated these associations. Data derived from a
randomized controlled trial comparing CBT (n = 43) and MI-CBT (n = 42) for GAD.
Independent observers reliably coded CT/CCT during session 1. Patients rated their
worry after every session. Multilevel modeling revealed that, across both treatments,
more CT associated with lower midtreatment worry level (p = .03), whereas more CCT
associated with a slower rate of worry reduction at midtreatment (p = .04). However,
treatment moderated the associations between CT and both midtreatment worry level (p =
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.004) and rate of change (p = .03). In CBT, patients with higher vs. lower CT had less
worry and a faster rate of worry reduction; in MI-CBT, CT was unrelated to midtreatment
worry level and the rate of worry change. Treatment did not moderate the CCT-worry
relations. Survival analyses revealed that, across both treatments, more CT associated
with a greater hazard of response (p = .004) and approached a faster time to response (p =
.05), and more CCT associated with a lower hazard of response (p = .002) and
approached a slower time to response (p = .06). Patient motivational language predicts
proximal outcomes, and may be useful in differential treatment selection.
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CHAPTER 1
INTRODUCTION

Generalized anxiety disorder (GAD) is a commonly-occurring condition, with a
12-month prevalence of 2.9% for adults (American Psychiatric Association, 2013). GAD
is also highly comorbid with other psychological problems; in a large stratified sample (N
= 8,098) across 172 countries, 90.4% of participants who met criteria for GAD also
reported a lifetime history of another mental disorder (Wittchen, Zhao, Kessler, & Eaton,
1994). Moreover, GAD is debilitating, with sufferers experiencing substantial impairment
across the domains of education, career development, economic productivity, and social
relationships (Mendlowicz & Stein, 2002; Wittchen, Carter, Pfister, Montgomery, &
Kessler, 2000). Thus, the need for effective GAD treatments is well-established.
The most prominent psychosocial treatment for this condition is cognitivebehavioral therapy (CBT), which has proven somewhat effective in reducing the hallmark
GAD symptom of pathological worry (Covin, Ouimet, Seeds, & Dozois, 2008). Yet,
overall, CBT for GAD response rates remain somewhat sobering. Across two metaanalyses, less than 50% of patients achieved clinically significant improvement by
treatment termination (Hunot, Churchill, Teixeira & Silve de Lima, 2007; Westen &
Morrison, 2001). Thus, there remains clear room for refinement, even for the current
“gold-standard” intervention.
Specific to CBT for GAD, some have posited that one patient-level characteristic
that may inhibit treatment response is low motivation for change (Arkowitz & Westra,
2004; Engle & Arkowitz, 2006; Westra, 2004, 2012). This low motivation may, in part,
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be related to the nature of the pathology, as people with GAD typically possess some
ambivalence about relinquishing their worry (Borkovec & Roemer, 1995). On the one
hand, these individuals may be driven to reduce the disability that results from excessive
and uncontrollable worry; on the other hand, such worry can be seen as an adaptive
mechanism of readiness and control (Borkovec, 1994; Newman, Llera, Erickson,
Przeworski, & Castonguay, 2013). Thus, the reliable assessment of patient motivation
may provide important information for effectively treating persons with GAD.
However, measuring motivation has proven challenging. Self-report measures
have been historically unreliable predictors of clinical outcomes in CBT for anxiety
disorders (Kampman, Keijsers, Hoogduin, & Hendriks, 2008; Poulin, Button, Westra,
Constantino, & Antony, 2018; Vogel, Hansen, Stiles, & Gotestam, 2006). For example,
in one study of CBT for GAD, only one of two self-report measures related to both
proximal and distal outcomes, whereas an observational measure of patients’ in-session
resistance (one potential manifestation of low, or at least conflicted, change motivation)
consistently predicted outcomes in the expected direction (Westra, 2011). Moreover,
when the self-report measures of motivation and the observer-based measure of insession resistance were included together in a simultaneous regression, only observercoded resistance predicted posttreatment worry. Westra posited that self-report measures
of motivation may be more susceptible to social desirability bias than observer measures
of related constructs; that is, although patients may be reticent to explicitly report low
motivation to change, such low motivation may be reliably revealed through observation
of in-session processes of resistance that suggest low change drive.
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In light of these comparative data sources, it seems that relying on explicit selfreport of motivation may be limiting. Moreover, in-session resistance, although certainly
a useful construct to assess, may reflect a consequence of low motivation, as opposed to
the low motivation construct itself. Fortunately, there is a promising way to combine an
explicit focus on motivation proper with objective observations. This method relies on
coding patient language content that implicitly reflects differing levels of motivation
(Glynn & Moyers, 2009). Rooted in self-perception theory (Bem, 1967) and cognitive
dissonance theory (Festinger, 1962), change-talk (CT) represents language in favor of
adaptive behavior change, while counter change-talk (CCT) represents language in favor
of maintaining the problem behavior (Miller & Rollnick, 2002).
Studies to date have supported the predictive validity of these two types of
motivational language across various treatments for various disorders. For example, in a
meta-analysis of studies targeting behavior change with motivational interviewing (MI),
motivational enhancement therapy (MET), and brief motivational interventions, patient
CCT was negatively associated with adaptive outcomes (Magill et al., 2014). In another
study focused on MET for problem drinking, patient CT and CCT were shown to predict
positive and negative outcomes, respectively (Moyers et al., 2007). With regard to GAD
in particular, several studies focused on standard CBT for GAD have demonstrated that
variants of patient CCT, but not CT, were positively correlated with higher posttreatment
and/or follow up worry outcomes (Hunter, Button, & Westra, 2013; Lombardi, Button, &
Westra, 2014; Sijercic, Button, Westra, & Hara, 2016). In another study of GAD, this
time across patients receiving either CBT or CBT integrated with MI, variants of CCT
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again correlated positively with higher posttreatment and follow up worry outcomes,
whereas higher CT associated with lower worry at follow up only (Poulin et al., 2018).
In the extant GAD research base examining associations between motivational
language and treatment outcomes, CT and CCT have largely been assessed at baseline or
early treatment, while the outcome variables have largely been assessed distally at
posttreatment and/or follow up. To date, little attention has been paid to early treatment
CT and CCT as predictors of more proximal outcomes, such as trajectories of
dimensional symptom change over the course of active treatment, the “hazard” of
obtaining a clinically significant response at some point during treatment, or the time it
takes for patients to reach clinically significant response criteria. Furthermore, with the
exception of the Poulin et al. (2018) study, research examining the CT/CCT-outcome
relations has tended to do so within single-school treatments only (e.g., MI or CBT
alone). Thus, it seems important to continue to examine these questions in newer
generation therapies for GAD that have integrated into CBT strategies that address some
theoretically important and previously neglected feature of the disorder in an effort to
improve patient response (e.g., Dugas et al., 2010; Newman et al., 2011; Wells et al.,
2010).
For example, in a recent trial, investigators tested the value of responsively
integrating MI into CBT, as a means to increase patients’ intrinsic motivation and change
agency (Westra, Constantino, & Antony, 2016). Although there were no differences
between standard CBT and MI-CBT at posttreatment, patients in MI-CBT showed
significantly greater worry reduction across a 12-month follow up than CBT alone
patients. These findings not only support the added efficacy for the integrative treatment
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adaptation, but they also support examining predictors of change, like motivational
language, in both standard CBT and the newer generation integrative CBT.
Finally, it also seems important to address whether treatment type (e.g., a singleschool approach vs. an integrative approach) might formally moderate the languageoutcome associations. As there is no research or theory to suggest that language-outcome
associations should systematically vary based on treatment, several rival ideas can be
examined. On the one hand, it could be that language has stronger effects on outcomes
(negative or positive) when a therapist addresses low motivation in a directive manner, as
is the case when CBT therapists treat low change drive as a problem or distorted
cognition to be actively challenged and resolved. Alternatively, language may have
stronger effects on outcomes when the therapist responds to low motivation in a nondirective, patient-centered, and autonomy-preserving manner, as is the case in MI-CBT.
If such systematic variability exists, in whatever direction, it can inform future theory
generation and research on what therapy factors are most effective for which patients.
Extending the extant literature and drawing on data from the aforementioned
Westra et al. (2016) trial, the goals of the present study were to test CT and CCT as
predictors of (a) change in worry across acute treatment, (b) hazard of clinically
significant response, and (c) time to clinically significant response across both standard
CBT and MI-CBT for GAD. Consistent with the literature, we predicted that CT would
be associated with steeper acute phase symptom reduction and a faster time to response,
whereas CCT would have the opposite effect on these outcomes. Our question of whether
treatment type (CBT vs. MI-CBT) would moderate these language-outcome associations
was novel and exploratory.

5

CHAPTER 2
METHOD

2.1 Participants
Patients were 85 adults randomly assigned to receive 15 sessions (50 minutes
each) of either MI-CBT (n = 42) or CBT (n = 43) at one of two sites in Toronto, Canada.
To be included in the trial, patients had to meet Diagnostic and Statistical Manual of
Mental Disorders versions IV, Text Revision (DSM-IV-TR; American Psychiatric
Association, 2000) and 5 (DSM-5; American Psychiatric Association, 2013) criteria for
principal GAD, and score above a high worry severity cutoff of ≥ 68 on the Penn State
Worry Questionnaire (PSWQ; Meyer, Miller, Metzger & Borkovec, 1990; described
below). To enhance generalizability, most comorbid diagnoses were allowable. Also,
although unmedicated patients were required to remain unmedicated during the trial,
being on antidepressant medication was allowable if the individual was using the same
medication and dose for at least 3 months prior to study inclusion and agreed to remain
on this dose throughout treatment. Exclusion criteria were concurrent psychotherapy,
benzodiazepine use, psychotic spectrum disorders or bipolar disorder, major cognitive
impairment, substance dependence within the past 6 months, and significant current
suicidal ideation.
Therapists were 21 female doctoral students in clinical psychology programs who
self-selected to treat patients in either MI-CBT (n = 9) or CBT (n = 12). This nesting was
designed to mitigate allegiance effects. The MI-CBT therapists’ caseloads ranged from 1
to 13 cases (Mdn = 4), while CBT therapists’ caseloads ranged from 1 to 6 cases (Mdn =
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4). Therapists were trained through a combination of workshops and readings, and they
were only allowed to treat study cases after demonstrating competence with at least one
practice case. During the trial, supervision was provided by an expert in each condition,
and it consisted of weekly individual meetings and video review.

2.2 Treatments
2.2.1 CBT
For both conditions, therapists delivered CBT according to multiple evidencebased protocols for treating GAD (Borkovec & Costello, 1993; Borkovec & Mathews,
1988; Borkovec, Newman, Pincus, & Lytle, 2002). Targeting the core features of GAD,
including uncontrollable worry, inhibited emotional processing secondary to worry, and
chronic hyperarousal, this multi-component treatment included psychoeducation about
worry/anxiety, exposure to worry and worry cues, applied relaxation, behavioral
approach tasks, self-monitoring of thoughts, and challenging of distorted cognitions.
Therapists managed patient resistance using techniques recommended in the CBT
literature (e.g., functional analysis, collaborative goal setting, problem-solving; Beck,
2005; Sanderson & Bruce, 2007; Tompkins, 2004).

2.2.2 MI-CBT
Therapists delivered the integrative treatment according to Westra’s (2012) guidelines for
assimilating MI principles (Miller & Rollnick, 2002) into action-oriented treatments (like
CBT) for anxiety. Applied to GAD, MI is a person-centered approach focused on helping
patients resolve ambivalence about reducing their worry and addressing interpersonal

7

resistances that might stem from such ambivalence. MI-specific strategies include
helping patients develop discrepancies between their current experiences and their most
valued experiences (to promote self-arguments for moving toward their valued self) and
purposefully “rolling with” patient resistance by empathically exploring both the positive
and negative aspects of behavior change, while validating and normalizing ambivalence
about changing.
Procedurally, patients first received up to 4 preparatory sessions of MI, followed
by 11 CBT sessions with MI responsively integrated. Although the typical patient
received all 4 of the “pure” MI sessions, for patients who were highly motivated for
change-oriented interventions, the shift to CBT occurred 1 to 2 sessions earlier. In the
subsequent CBT-based sessions, therapists continued to use MI “spirit” (collaboration,
empathy, validation, evocation, and enhancing self-efficacy) as a foundational stance, and
they explicitly shifted into primary MI strategies in response to markers of patient
resistance. Once a resistance episode was deemed resolved, therapists shifted back into
CBT with MI spirit. These marker-driven responsive shifts occurred as needed. Therapist
adherence to their respective treatment protocol was observer-rated on a random subset of
20% of sessions for each therapist in each condition. As expected, adherence to CBT was
high across both conditions, with adherence measures discriminating between conditions
on the key components of preparatory and responsively integrated MI (see Westra et al.,
2016, for details).
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2.3 Measures

2.3.1 Patient Motivational Language
CT and CCT were observer-assessed according to an adapted (for CBT; Lombardi
et al., 2014) version of the Motivational Interviewing Skills Code 1.1 (MISC 1.1; Glynn
& Moyers, 2009). In this coding system, patient language across an entire session is first
parsed into turns at talk, and then further deconstructed into utterances (i.e., complete and
separate thoughts). Patient utterances are then coded as CT language in favor of changing
the target behavior (e.g., “I want to stop worrying”) or CCT utterances in favor of
sustaining the target behavior (e.g., “Worry makes me work extra hard”). All other nonchange-related patient utterances are left uncoded (Button, Westra, Hara, & Aviram,
2015). The MISC has shown strong predictive validity in the treatment of problem
drinking (Magill et al., 2014; Moyers et al., 2007) and GAD (e.g., Hunter et al., 2013;
Lombardi et al., 2014; Poulin et al., 2018).
The adapted MISC 1.1 coders were two upper-level undergraduate students in
psychology and a clinical psychology master’s level graduate student. Coders were
trained over four months, participating in two 3-hour training workshops and
independently coding test material to determine proficiency. The study coders all
achieved 85% observed agreement with criterion codes for the test materials. For the
current study, 25% of the material was double coded to determine interrater reliability.
Kappa coefficients for each pair of coders indicated good to excellent interrater reliability
(average к = .86).
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2.3.2 Worry
The primary outcome variables for this study were derived from the PSWQ
(Meyer et al., 1990), a widely-used self-report measure of trait worry. All 16 items are
rated on a 5-point scale ranging from 1 to 5, with higher total scores reflecting more
worry (range = 16 to 80). The PSWQ has sound psychometric properties (Brown, Antony,
& Barlow, 1992; Meyer et al., 1990), and it demonstrated high internal consistency across
the repeated measures in this study (average α = .93).

2.4 Procedure
Participants responded to community advertisements posted in the greater
Toronto area. After responding, potential participants were phone screened. If eligible, a
trained graduate assessor administered the Structured Clinical Interview for DSM-IV-TR
Axis I Disorders (SCID-I; First, Spitzer, Gibbon, & Williams, 1996) to consenting
participants to determine diagnostic eligibility and assess other clinical features. Eligible
patients were then randomized to treatment across the two sites. The randomization
protocol was administered at a neutral third site by a co-investigator uninvolved in site
procedures and therapist training, and blind to patient clinical features. The MISC 1.1
was applied to motivational language uttered in the first session. The PSWQ was
administered at baseline and after every session. The institutional review boards at the
two data collection sites approved the trial, as well as subsequent secondary analyses of
de-identified data.
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2.5 Data Analysis
First, to control for patient verbosity, ratios of CT and CCT frequencies to total
session utterances were created, and these ratios were used as the predictor variables in
all analytic models. Second, we calculated descriptive statistics for patient and therapist
samples and all study variables, including their distributions and potential outliers. Third,
we examined the intercorrelations among all study variables to determine if there were
any problems of collinearity (e.g., between the baseline self-report variable of change
motivation and session 1 motivational language). Finally, we addressed the primary
research questions with three separate sets of analyses.
To examine the relation between patient motivational language and change in
worry during the acute treatment phase, we used multilevel modeling given its ability to
account for dependencies in the data due to repeated measures.1 As our primary focus
was on proximal rather than distal outcomes, time for the multilevel models was centered
at midtreatment (session 7.5). Using the hierarchical linear modeling program (HLM7;
Raudenbush, Bryk, & Congdon, 2011), we first fit two individual 2-level models (one for
CT and one for CCT) to estimate within patient change in worry at level-1, and between
patient differences in worry change at level-2. Visual inspection of the average rate of
change in worry revealed a slight curvature. Thus, we first fit an unconditional linear
model, and then an unconditional quadratic model to determine which model was a better
fit to the data. Then, at level-2, we examined the effect of patient CT and CCT,

1

Although there is another source of dependency in these data (i.e., patients nested within therapists),
we did not examine therapist effects on worry given that Westra et al. (2016) found that the therapist
accounted for < 1% of the variability in patients’ posttreatment worry and during-treatment rates of change
in worry.
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respectively, on worry trajectories. To assess whether treatment condition moderated the
association of each language variable and worry change, we added CT x treatment and
CCT x treatment interaction terms to their respective model. Effect sizes were calculated
by evaluating the additional percent variance explained with the addition of predictors (a
pseudo r2 statistic).
To examine the relation between patient motivational language and the hazard of
clinically significant response (i.e., the instantaneous “risk” of achieving the response
criteria at the next session), we used R: A language and environment for statistical
computing (R Core Team, 2015) to estimate survival models. To determine statistically
reliable and clinically significant response, we used Jacobson and Truax’s (1991) criteria,
as Westra et al. (2016) did in the flagship outcome report for this trial; namely, to be
considered a responder, patients had to pass an empirically derived cut point for reliable
response (the Reliable Change Index; RCI) and clinically meaningful response (i.e.,
Cutoff C). Drawing on Gillis, Haaga, and Ford’s (1995) normative data, the PSWQ has a
RCI of 9 and a Cutoff C of 58 (i.e., a score of  58 is closer to the normal than clinical
range). Thus, we defined response as a decrease of 9 points on the PSWQ, with a score of
 58.
As the underlying hazard function for our variables was unknown, and the
negative statistical repercussions of inaccurately specifying the hazard function are high,
we used the semi-parametric Cox model (Cox, 1972) for our analyses. Though Cox
models relax assumptions compared to fully parametric models (e.g., the Weibull
proportional hazards model), there are two assumptions that need to be met to ensure
reliability of Cox model estimates: non-informative censoring and proportional hazards.
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To test the assumption that censoring was non-informative, we conducted a sensitivity
analysis, first treating all censored cases as though they achieved clinically significant
response at the time of censoring, and then treating all censored cases as though they
achieved clinically significant response at the time point when the majority of patients
achieved clinically significant response.
The assumption of proportional hazards is met when the ratio of hazards for any
two patients is constant and is not time dependent. We tested this assumption through
visual inspection of Schoenfeld residual plots, and the cox.zph function in R, which
assessed the correlation of predictor variables with time. For any variable that violated
this assumption, a time-varying covariate was created and included in the final model. In
addition to the predictors of interest (CT and CCT), we also assessed whether treatment
condition moderated the association of each language variable and hazard of response by
adding CT x treatment and CCT x treatment interaction terms to our final model. Finally,
to examine the relation between patient motivational language and time to clinically
significant response, we used Kaplan Meier curves.
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CHAPTER 3
RESULTS

3.1 Preliminary Analyses
The mean CT and CCT ratios were 0.18 (SD = 0.11) and 0.11 (SD = 0.07),
respectively. These variables did not significantly differ between conditions – CT: t(82.5)
= -1.28, p = .20; CCT: t(82.5) = 1.05, p = .30. CT was non-normally distributed, with
skewness of 2.20 (SE = 0.26) and kurtosis of 8.15 (SE = .52). CCT was also nonnormally distributed, with skewness of 1.46 (SE = 0.26) and kurtosis of 3.30 (SE = .52).
Thus, we performed square root transformations on both predictors. The transformed CT
has a skewness of 0.96 (SE = 0.26) and kurtosis of 1.91 (SE = .52), and the transformed
CCT has a skewness of 0.31 (SE = 0.26) and kurtosis of 0.67 (SE = .52). Inspection of QQ and stem-and-leaf plots revealed two statistical outliers for our predictor variables
(CCT, z = 4.206; CT, z = 5.206). However, there was no reason to believe that these
extreme values were a function of data entry or measurement error. Thus, they were
considered legitimate observations and included in our analyses. Intercorrelations
between predictors were weak to moderate (rs range from -.130 to .319).
Table 1 presents the sample descriptive statistics by treatment condition. Between
treatments, patients did not differ on baseline PSWQ or any demographic variable other
than gender; there were more women and less men in the CBT vs. MI-CBT condition, χ2
(1) = 4.24, p = .04. The groups differed significantly on baseline motivation for change,
as assessed by the Change Questionnaire (CQ; Miller & Johnson, 2008), which includes
12 items rated on a scale from 0 to 10. Specifically, CBT patients reported significantly
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higher motivation than MI-CBT patients, t(83) = -2.55, p = .013. Furthermore, between
group differences in medication status approached significance, with more CBT patients
reporting medication use than MI-CBT patients, χ2 (1) = 3.94, p = .05. For our first
primary research question, given the two treatment sites and the fact that the treatment
groups differed on baseline change motivation and antidepressant medication status, we
residualized out the effects of site, motivation, and medication from the PSWQ variable,
as was done in the flagship outcome analyses for this trial (Westra et al., 2016). Thus, our
variable for the multilevel models presented below represents the variability in worry that
is not accounted for by these three baseline variables. For our second primary research
question, we included site, baseline self-report motivation, and medication status as
covariates in our model.
Returning to the trial characteristics, attrition during the active treatment phase
included 23% (n = 10) of CBT patients and 10% (n = 4) of MI-CBT patients. This
differential attrition rate approached significance, χ2 (1) = 2.91, p = .09. Regarding
therapists, they did not significantly differ between groups on age (MI-CBT, M = 28.33
years; CBT, M = 29.08 years), t(19) = -.482, p = .64, or clinical experience (MI-CBT, M
= 451.53 hours; CBT, M = 190.21 hours), t(7.20) = 1.13, p = .293.

3.2 Motivational Language and Worry Change
Results of the model comparison test indicated that the unconditional quadratic
model (see Table 2, column 1) was a significantly better fit to the data than the
unconditional linear model, χ2(4) = 85.32, p < 0.001. We therefore used this quadratic
model for our HLM analyses. To examine the CT-worry association, we added the
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session 1 CT ratio to the quadratic model as a predictor at level-2 (see Table 2, column
2). Higher CT was associated with lower worry at midtreatment (γ02 = -22.10, p = .03),
accounting for 5% of the unexplained variance. Additionally, higher CT was marginally
associated with greater worry reduction at midtreatment (γ12 = -2.32, p = .06), accounting
for 4% of the unexplained variance. CT was unrelated to the rate of
acceleration/deceleration in worry change across treatment. As per Table 2, column 3, the
CT x treatment interaction term significantly predicted worry at midtreatment (γ03 =
47.33, p = .03) and the rate of change in worry at midtreatment (γ13 = 5.47, p = .03);
namely, in CBT, more session 1 CT was associated with a lower level of worry and a
greater decrease in worry at midtreatment, whereas in MI-CBT, CT was unrelated to
worry level and worry change at midtreatment. This moderating effect is graphically
depicted in Figure 1. Finally, the CT x treatment interaction term was unrelated to the
rate of acceleration/deceleration in worry change across treatment.
To examine the CCT-worry association, we added the session 1 CCT ratio to the
quadratic model as a predictor at level-2 (see Table 3, column 2). Higher CCT was
associated with less worry reduction at midtreatment (γ12 = 2.88, p = .04), accounting for
2% of the unexplained variance. CCT was unrelated to worry level at midtreatment and
the rate of acceleration/deceleration in worry change across treatment. As per Table 3,
column 3, the CCT x treatment interaction term was unrelated to worry level at
midtreatment, the rate of change in worry at midtreatment, or the rate of
acceleration/deceleration in worry change across treatment.
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3.3 Motivational Language and Hazard of Clinically Significant Response
To examine the relation between patient motivational language and the hazard of
clinically significant response, we conducted a Cox proportional hazards model, with the
ratio of session 1 CT, the ratio of session 1 CCT, treatment group, a CT x treatment
interaction term, and a CCT x treatment interaction term as predictors. (As noted, site,
baseline self-report motivation, and medication status were included as covariates.) We
first conducted a sensitivity analysis to test the assumption of non-informative censoring
with the ratio of session 1 CT, the ratio of session 1 CCT, and treatment group. In our
first model (see Table 4), all randomly censored cases were treated as though they
experienced clinically significant response immediately after being censored (n = 85,
number of events = 85). In our second model (see Table 5), all randomly censored cases
were treated as though censoring occurred at the time-point when the majority of patients
experienced clinically significant response (n = 85, number of events = 58). Comparison
of the results of these two models indicated partially informative censoring, with
variation between models particularly apparent in the differences in the coefficient for
treatment group, β = -.04, p = .079; β = -.07, p = .79. However, in both of these extreme
models, coefficients and p-values for our primary predictors of interest (CT and CCT)
changed little, and we have no reason to believe that one of these extreme models is more
accurate that our original model.
Next, visual inspection of Schoenfeld residual plots did not indicate that the
hazard of predictors varied with time. However, the cox.zph function in R, which
correlates corresponding scaled Schoenfeld residuals with time, indicated that the
proportional hazards assumption had been violated. In particular, session 1 CCT was
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significantly correlated with time (p = 0.021). All other predictors, and the global test of
the model, were not significantly correlated with time. To correct for the violation of
proportional hazards, a CCT x time interaction term was added to our model. Our final
Cox model with predictors, covariates, and interaction terms can be seen in Table 6.
Results indicated that session 1 CT was a significant predictor in this model (HR = 1.04,
p = 0.004), such that for every 1 unit increase in session 1 CT, there was 4.12% increase
in the hazard of clinically significant response. Session 1 CCT was also a significant
predictor (HR = 0.87, p = 0.002), such that for every 1 unit increase in session 1 CCT,
there was a 7.44% decrease in the hazard of clinically significant response. Treatment
group was also a significant predictor (HR = 0.58, p = 0.05), indicating that the hazard of
clinically significant response for the CBT-only group was 72% that of the MI-CBT
group.

3.4 Motivational Language and Time to Clinically Significant Response
To estimate the survival function for clinically significant response at differing
levels of session 1 CT and CCT we used the Kaplan Meir estimator, with corresponding
plots of the survival function. Patients in the upper 75th percentile of session 1 CT had a
median time to clinically significant response of 5 weeks, compared to a median time to
clinically significant response of 9 weeks for the remainder of the sample, χ2 (1) = 3.80, p
= .05 (see Figure 2, Panel A). Patients in the upper 75th percentile of session 1 CCT had a
median time to clinically significant response of 14 weeks, compared to a median time to
clinically significant response of 7 weeks for the remainder of the sample. However, the
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difference between these survival estimates only approached significance, χ2 (1) = 3.5, p
= .06 (see Figure 2, Panel B).
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CHAPTER 4
DISCUSSION

We tested CT and CCT as predictors of (a) change in worry across acute
treatment, (b) hazard of clinically significant response, and (c) treatment efficiency, or
time to clinically significant response, across both standard CBT and integrative MI-CBT
for GAD. Regarding the relation between patient motivational language and worry level
and change, CCT associated with a slower rate of worry reduction at midtreatment across
both treatments. With regard to CT, CBT patients with higher vs. lower CT had less
worry and a faster rate of worry reduction, whereas for MI-CBT patients, CT was
unrelated to the worry outcomes. Regarding the relation between patient motivational
language and clinically significant response, across both treatments, more CT associated
with a greater hazard of response, and more CCT associated with a lower hazard of
response (with each variable predicting efficiency of response in a consistent manner, but
at a trend level).
Our results generally replicate previous research patterns that link CT and CCT,
especially when observed through language, with positive and negative outcomes,
respectively (e.g., Moyers et al., 2007; Magill et al., 2014; Poulin et al., 2018). They
extend prior research by showing that these associations largely hold for the more
proximal outcomes vs. distal, posttreatment outcomes only, and whether receiving
standard CBT or integrative MI-CBT for GAD. In this sense, patients engaging in more
CT is a common facilitating factor, whereas engaging in more CCT is a common
hindering factor, both of which can be informative for case conceptualization and
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treatment planning. Thus, our results continue to highlight the importance of patient
motivational language as a clinical prognosticator of varied forms of dimensional and
categorical treatment response; that is, the likelihood that standard or adapted CBT will
work for a given patient with GAD (with regard to dimensional symptom reduction or
crossing a clinical significance threshold), and how long it might be expected to take
before showing its ameliorative effect.
Regarding the latter outcome, it might be useful for clinicians to use motivational
language (of both types) as an important input into estimations of treatment dose. As the
present data suggest that higher CT and lower CCT will require fewer sessions for
response, whereas lower CT and higher CCT will require more sessions (though not an
inordinately higher number), therapists can use this information to educate their patients
on expected time course at treatment’s outset. Such education has been shown to change
patients’ duration expectations and to reduce dropout and facilitate treatment engagement
(Swift & Callahan, 2011). Of course, this implication should be considered with caution
given that CT and CCT related only marginally to treatment efficiency. Future research is
needed to confirm or disconfirm the relevance of these variables for time to response, and
to test directly associations among motivational language, treatment expectancies,
treatment processes, and treatment outcomes.
Of additional note in the present study is that treatment condition moderated the
association between CT and dimensional worry level and change and midtreatment.
Given that CT related to these outcomes in CBT, but not MI-CBT, we can draw on the
stages of change literature to frame these differential results. Namely, Prochaska,
Norcross, and DiClemente’s (2013) transtheoretical model emphasizes the importance of
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matching appropriate therapy modalities to the patient’s readiness to change. In this case,
highly motivated patients who are in, for example, the preparation stage may derive less
benefit from therapies using MI spirit and strategy to address the resistance to, or low
motivation for, change that would be hallmarks of the earlier readiness stages (e.g.,
precontemplation) for which MI was explicitly developed. Instead, these motivated
patients, as indicated in their higher change-oriented language, might be prepared to
benefit immediately from more action-oriented therapies, such as CBT. For those with
lower CT, CBT might be outpacing their change readiness, thereby by resulting in less
improvement over acute treatment.
In MI-CBT, it is possible that MI levels the playing field, so to speak, for those
with lower vs. higher change readiness, as indicated in their CT language. Put differently,
for patients with lower CT, the integration of MI can help them overcome this risk factor
given its explicit focus on low intrinsic motivation. However, for patients with higher CT
(essentially when presenting for treatment), MI might actually interfere with this
facilitative factor, thereby delaying the benefit that these change-ready patients might
receive from change-oriented interventions. In these ways, MI might mitigate the
negative effect of low motivation, but also dampen the positive effect of high motivation,
essentially negating the influence of language on proximal outcomes.
Thus, our moderator results may have implications for treatment assignment, at
least in the context of standard CBT or integrative MI-CBT for GAD. When a patient is
assessed as engaged in high CT as early session 1, CBT may be the most indicated
intervention. For patients exhibiting low CT in session 1, MI-CBT may be the most
indicated. Of course, when patients exhibit high CCT, therapists doing either treatment
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will need to attend to this risk factor for poor proximal outcomes. Future work is needed
to identify the best strategies for doing so, as it may be somewhat surprising that using
MI integratively did not mitigate such risk. Additionally, future work is also needed to
replicate our findings with regard to the CT by treatment interaction, as this moderation
effect emerged for only one of our outcome variables (i.e., dimensional worry change).
This study had several limitations. First, although it intentionally investigated CT
and CCT as independent predictors of proximal treatment response, these language
variables do not exist in a vacuum. In fact, most patients, across any sample or type of
clinical population, would likely make both CT and CCT statements. Thus, future
research should examine the interaction of these variables in order to tease apart how
their variance combinations may influence treatment outcomes. For example, it is
possible that a combination of both high CT and high CCT may reflect change
ambivalence, which is another construct that has been associated with treatment
resistance, and that could have implications for treatment response.
Second, treatment response in our survival models was treated as a finite vs. a
repeated event. This way of measuring response could overlook nuance in that a patient
could achieve clinically significant response at one point in therapy, but then return to a
level of symptom severity above the response criterion at another point, and perhaps even
dip back below it at yet another time, etc. Third, although our study framed patient
motivational language essentially as a presenting patient trait, future research should look
beyond the single early time point to better understand language as a state (and how
change in motivational language relates to both proximal and distal treatment outcomes
in treatments for GAD). Finally, the generalizability of our findings is limited by our
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sample of mostly white women with severe worry. Future research should investigate
whether these patient language-outcome relations hold in other GAD treatment samples
of differing demographic characteristics and of lesser worry severity.
Limitations notwithstanding, the present study adds to the limited research on the
patient motivational language-outcome association in the treatment of anxiety disorders.
The results point to potential clinical implications of CT and CCT, especially as they
relate to treatment selection and prognostication of the proximal outcomes that
complement posttreatment symptom reduction and functional improvement. With
additional research that extend to patients with different diagnoses who are receiving
therapy modalities beyond MI and CBT, it can be determined if patient motivational
language reaches the level of a transdiagnostic and pantheoretical clinical prognosticator.
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APPENDIX A
TABLES
Table 1
Participant Characteristics at Baseline by Treatment Condition
Variables
Age
Sex*
Female
Male
Race
Caucasian
Asian
African Canadian
Hispanic
Multiracial
Annual household income
Less than 25,000
25,000-50,000
50,000-75,000
75,000-100,000
100,000 or more
Education
High school or less
Some college/university
Completed college
Some graduate school
Marital statusa
Single
Cohabiting/married
Current medication use*
Yes
No
Previous psychotherapy
Yes
No
Comorbidityb
Anxiety disorder
Depression/dysthymia
Outcome variable
PSWQ
CQ*

M
34.19

75.05
107.23

CBT (n = 43)
SD
N
11.92

%

M
32.45

MI-CBT (n = 42)
SD
n
%
10.54

41
2

95.34
4.65

34
8

80.95
19.05

32
5
0
2
3

74.42
11.62
0.00
4.65
6.98

31
6
2
1
2

73.81
14.29
4.76
2.38
4.76

10
9
11
8
5

23.26
20.93
25.58
18.60
11.63

6
8
8
6
13

14.29
19.05
19.05
14.29
30.95

4
13
18
8

9.30
30.23
41.86
18.60

2
9
19
12

4.76
21.43
45.24
28.57

19
23

44.19
54.76

18
24

42.86
57.14

14
29

32.56
67.44

6
36

14.29
85.71

32
11

74.42
25.58

31
11

73.81
26.19

31
17

72.09
39.53

29
13

69.05
30.95

3.43
8.76

74.69
101.60

3.44
11.50

Note. M = mean; SD = standard deviation; PSWQ = Penn State Worry Questionnaire; CQ
= Change Questionnaire.
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a

Category sums to less than 43 (and less than 100%) for the CBT condition due to
missing data.
b
Category sums to more than each group’s sample size due to some patients having more
than one comorbid disorder.
* Groups differences on these variables at baseline were either significant or approached
significance (p  .05).
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Table 2
Change-Talk as a Predictor of Midtreatment worry, Subsequent Worry Change, and Subsequent
Acceleration/Deceleration in the Rate of Worry Change

Fixed Effects
Midtreatment PSWQ (intercept), γ00
Treatment group, γ01
Change-talk session 1, γ02
Change-talk x treatment, γ03
Midtreatment change in PSWQ (slope), γ10
Treatment group, γ11
Change-talk session 1, γ12
Change talk x treatment, γ13
Rate of acceleration/deceleration in PSWQ
(curvature), γ20
Treatment group, γ21
Change-talk session 1, γ22
Change-talk x treatment, γ23
Random effects
PSWQ intercept, 00
PSWQ slope, 11
PSWQ curvature, 22
Level 1, σ2
Model deviance (df)

Unconditional model
Coefficient (SE)
p
2.15 (1.21)
.079
-------1.67 (0.15)
< .001
------0.01 (0.2)
.651
-----Variance
component
112.54
1.64
0.02
44.06
8606.48(10)

-----p
< .001
< .001
< .001
---

Note. PSWQ = Penn State Worry Questionnaire, CT = session 1 change-talk
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CT only model
Coefficient (SE)
2.19 (1.18)
-0.77 (2.37)
-22.10 (10.03)
--1.66 (0.14)
0.05 (0.29)
-2.32 (1.22)
-0.01 (0.02)
0.01 (0.04)
0.20 (0.15)
---Variance
component
106.28
1.58
0.02
44.06
8600.48 (16)

p
.066
.746
.030
-< .001
.874
.060
-.682
.879
.181
-p
< .001
< .001
< .001
---

CT x Tx model
Coefficient (SE)
1.87 (1.15)
-0.65 (2.30)
-30.03 (10.37)
47.33 (20.73)
-1.70 (0.14)
0.06 (0.28)
-3.21 (1.25)
5.47 (2.50)
0.01 (0.02)
0.01 (0.04)
0.26 (0.16)
-0.29 (.32)
Variance
component
99.46
1.48
0.02
44.06
8594.44 (19)

p
.108
.778
.005
.025
< .001
.818
.012
.032
.596
.880
.113
.362
p
< .001
< .001
< .001
---

Table 3
Counter Change-Talk as a Predictor of Midtreatment worry, Subsequent Worry Change, and
Subsequent Acceleration/Deceleration in the Rate of Worry Change

Fixed Effects
Midtreatment PSWQ (intercept), γ00
Treatment group, γ01
Counter change-talk session 1, γ02
Counter change-talk x treatment, γ03
Midtreatment change in PSWQ (slope), γ10
Treatment group, γ11
Counter change-talk session 1, γ12
Counter change talk x treatment, γ13
Rate of acceleration/deceleration in PSWQ
(curvature), γ20
Treatment group, γ21
Counter change-talk session 1, γ22
Counter change-talk x treatment, γ23
Random effects
PSWQ intercept, 00
PSWQ slope, 11
PSWQ curvature, 22
Level 1, σ2
Model deviance (df)

Unconditional model
Coefficient (SE)
p
2.15 (1.21)
.079
-------1.67 (0.15)
< .001
------0.01 (0.2)
.651
-----Variance
component
112.54
1.64
0.02
44.06
8606.48(10)

-----p
< .001
< .001
< .001
---

CCT only model
Coefficient (SE)
2.16 (1.19)
-0.90 (2.41)
15.95 (11.57)
--1.67 (0.14)
0.07 (0.29)
2.88 (1.37)
-0.007 (0.02)
0.02 (0.04)
0.13 (0.17)
---Variance
component
106.28
1.58
0.02
44.08
8599.61 (16)

Note. PSWQ = Penn State Worry Questionnaire, CCT = session 1 counter change-talk
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p
.074
.710
.172
-< .001
.796
.040
-.672
.660
.462
-p
< .001
< .001
< .001
---

CCT x Tx model
Coefficient (SE)
2.10 (1.20)
-0.85 (2.41)
16.75 (11.71)
-6.55 (23.43)
-1.66 (0.14)
0.07 (0.28)
2.80 (1.39)
1.26 (2.77)
0.010 (0.02)
0.01 (0.04)
0.10 (0.17)
0.24 (0.34)
Variance
component
109.01
1.55
0.02
44.09
85948.81 (19)

p
.086
.724
.157
.780
< .001
.803
.047
.651
.594
.686
.557
.501
p
< .001
< .001
< .001
---

Table 4
Randomly Censored Cases Treated as Though Experiencing Event Immediately After
Censoring
Β

SE

HR

95%CI(HR)

P

Change-talk session 1

0.03

0.01

1.03

1.01 - 1.05

.007

Counter change-talk session 1

-0.06

0.02

0.93

0.90 - 0.97

.001

Treatment group

-0.41

0.23

0.66

0.42 - 1.04

.079

Variable

29

Table 5
Randomly Censored Cases Treated as Though Experiencing Event at Largest Event
Time-Point
Β

SE

HR

95%CI(HR)

P

Change-talk session 1

0.04

0.01

1.04

1.02 - 1.07

.001

Counter change-talk session 1

-0.04

0.02

0.95

0.92 - 1.00

.047

Treatment group

-0.07

0.27

1.08

0.55 - 1.59

.790

Variable
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Table 6
Final Cox Proportional Hazards Model
β

SE

HR

95%CI(HR)

p

Change-talk session 1

0.04

0.01

1.04

1.01 - 1.07

.004

Counter change-talk session 1

-0.13

0.04

0.87

0.81 - 0.95

.001

Counter change-talk x Time

0.01

0.01

1.01

1.00 - 1.02

.092

Treatment group

-0.54

0.27

0.58

0.34 - 0.99

.470

Medication status

0.37

0.28

1.45

0.83 - 2.52

.191

Site
Motivation (Change
Questionnaire)
Change-talk x Treatment

-0.20

0.23

0.82

0.52 - 1.29

.395

0.01

0.01

1.00

0.98 - 1.02

.852

-0.04

0.03

0.96

0.91 -1.02

.166

Counter change-talk x Treatment

-0.02

0.04

0.98

0.90 -1.06

.575

Variable
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APPENDIX B
FIGURES

Figure 1. The moderating effect of treatment group on the CT-worry association. In CBT,
patients 1 standard deviation above the mean of session 1 CT had a greater decrease in
worry than patients 1 standard deviation below the mean. In the MI-CBT condition,
different levels of CT had a negligible impact on worry reduction.
Note. PSWQ = Penn State Worry Questionnaire, CT = session 1 change-talk
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Panel A

Panel B

Figure 2. Survival estimates for different levels of CT and CCT. Panel A depicts the
survival estimates for the upper 75th percentile of CT at session 1 compared to the rest of
the sample (0 = 75th percentile, 1 = remainder of the sample). Panel B depicts the survival
estimates for the upper 75th percentile of CCT at session 1 (0 = 75th %, 1 = remainder of
the sample).
Note. CT = session 1 change-talk; CCT = session 1 counter change-talk.
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